LTR Pharma Limited (ASX:LTP)
Australia · Delayed Price · Currency is AUD 0.4650
0.00 (0.00%)
Last updated: Sep 11, 2026, 10:37 AM AEST
LTR Pharma Revenue
In the fiscal year ending June 30, 2026, LTR Pharma had annual revenue of 723.94K AUD, down -52.01%. LTR Pharma had revenue of 650.19K in the half year ending June 30, 2026, with 1,226.86% growth.
Revenue
723.94K
Revenue Growth
-52.01%
P/S Ratio
116.76
Revenue / Employee
n/a
Employees
n/a
Market Cap
84.53M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 723.94K | -784.47K | -52.01% |
| Jun 30, 2025 | 1.51M | 1.46M | 2,978.25% |
| Jun 30, 2024 | 49.00K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 9.08K | - | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Botanix Pharmaceuticals | 33.80M |
| Immutep | 19.93M |
| Neurizon Therapeutics | 17.59M |
| Recce Pharmaceuticals | 9.47M |
| Amplia Therapeutics | 4.79M |
| Alterity Therapeutics | 3.61M |
| Arovella Therapeutics | 3.50M |
| Prescient Therapeutics | 3.45M |